Published August 5, 2021 | Version v1
Journal article Open

Bridging molecular basis, prognosis, and treatment of pediatric liver tumors

  • 1. Childhood Liver Oncology Group, Germans Trias I Pujol Research Institute (IGTP), Program of Predictive and Personalized Medicine of Cancer (PMPCC), Badalona 08916, Spain
  • 2. Pediatric hematology, oncology and hematopoietic cell & gene therapy lab, Istituto di Ricerca Pediatrica (IRP), Padova 35127, Italy.
  • 3. Department of Pediatric Surgery, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University Munich, Munich 80337, Germany.

Description

A deeper understanding of the genetic and molecular basis of hepatoblastoma (HB) has fueled the hope to help in identifying genes and signaling pathways that are amenable to therapeutic intervention. However, it has become clear that HB is a genetically very simple cancer and that rather alterations of the transcriptome or epigenome will facilitate a more stratified and rationalized approach to current therapeutics. In this review, we discuss recent findings on genomic, transcriptomic, and epigenomic data and their potential to serve as biomarkers and predictors of patient’s outcome. We also describe the state of the art in HB experimental biology, the in vitro and in vivo HB models that are currently available, and their use to improve our understanding of this disease and identify new treatment options.

Files

Brinding_Molecular_basis.pdf

Files (667.4 kB)

Name Size Download all
md5:6248d9fb0691451ef43c924f37b1245a
667.4 kB Preview Download

Additional details

Funding

iPC – individualizedPaediatricCure: Cloud-based virtual-patient models for precision paediatric oncology 826121
European Commission